Status:

COMPLETED

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Lead Sponsor:

Supernus Pharmaceuticals, Inc.

Conditions:

Partial Epilepsy

Eligibility:

All Genders

18-66 years

Phase:

PHASE3

Brief Summary

Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)

Detailed Description

NAP

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Able to provide written informed consent and agree to comply with study procedures.
  • Male or female aged 18 to 66 years, inclusive.
  • Successful completion of the 804P301 study.
  • Sexually active women, unless surgically sterile (at least 6 months prior to Study Medication \[SM\] administration) or at least 1 year post-menopausal, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives \[any hormonal method in conjunction with a secondary method\], intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of condom with spermicide by sexual partner or sterile \[at least 6 months prior to SM administration\] sexual partner) for at least four weeks prior to SM administration, and must agree to continue using such precautions through the End of Study visit. Cessation of birth control after this point should be discussed with a responsible physician.
  • Exclusion Criteria
  • Clinically significant change in health status that, in the opinion of the Investigator, would prevent the subject from participating in this study or successfully completing this study.
  • Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Exclusion

    Key Trial Info

    Start Date :

    June 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 1 2011

    Estimated Enrollment :

    214 Patients enrolled

    Trial Details

    Trial ID

    NCT00908349

    Start Date

    June 1 2009

    End Date

    November 1 2011

    Last Update

    May 31 2017

    Active Locations (58)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 15 (58 locations)

    1

    Huntsville, Alabama, United States

    2

    Northport, Alabama, United States

    3

    Phoenix, Arizona, United States

    4

    Tucson, Arizona, United States